Fiche du document
2016
- doi: 10.1101/gad.270439.115
- issn: 0890-9369
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.1101/gad.270439.115
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/26773004
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/eissn/1549-5477
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_34BF0625B5096
info:eu-repo/semantics/openAccess , Copying allowed only for non-profit organizations , https://serval.unil.ch/disclaimer
Sujets proches
Carcinoma Cancers Malignancy (Cancer) Malignant tumorsCiter ce document
L. Akkari et al., « Combined deletion of cathepsin protease family members reveals compensatory mechanisms in cancer. », Serveur académique Lausannois, ID : 10.1101/gad.270439.115
Métriques
Partage / Export
Résumé
Proteases are important for regulating multiple tumorigenic processes, including angiogenesis, tumor growth, and invasion. Elevated protease expression is associated with poor patient prognosis across numerous tumor types. Several multigene protease families have been implicated in cancer, including cysteine cathepsins. However, whether individual family members have unique roles or are functionally redundant remains poorly understood. Here we demonstrate stage-dependent effects of simultaneously deleting cathepsin B (CtsB) and CtsS in a murine pancreatic neuroendocrine tumor model. Early in tumorigenesis, the double knockout results in an additive reduction in angiogenic switching, whereas at late stages, several tumorigenic phenotypes are unexpectedly restored to wild-type levels. We identified CtsZ, which is predominantly supplied by tumor-associated macrophages, as the compensatory protease that regulates the acquired tumor-promoting functions of lesions deficient in both CtsB and CtsS. Thus, deletion of multiple cathepsins can lead to stage-dependent, compensatory mechanisms in the tumor microenvironment, which has potential implications for the clinical consideration of selective versus pan-family cathepsin inhibitors in cancer.